Differential Gene Expression Involved in Bone Turnover of Mice Expressing Constitutively Active TGFβ Receptor Type I
Issued Date
2024-06-01
Resource Type
ISSN
16616596
eISSN
14220067
Scopus ID
2-s2.0-85195841437
Journal Title
International Journal of Molecular Sciences
Volume
25
Issue
11
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Molecular Sciences Vol.25 No.11 (2024)
Suggested Citation
Myint O., Sakunrangsit N., Pholtaisong J., Toejing P., Pho-on P., Leelahavanichkul A., Sridurongrit S., Aporntewan C., Greenblatt M.B., Lotinun S. Differential Gene Expression Involved in Bone Turnover of Mice Expressing Constitutively Active TGFβ Receptor Type I. International Journal of Molecular Sciences Vol.25 No.11 (2024). doi:10.3390/ijms25115829 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98876
Title
Differential Gene Expression Involved in Bone Turnover of Mice Expressing Constitutively Active TGFβ Receptor Type I
Corresponding Author(s)
Other Contributor(s)
Abstract
Transforming growth factor beta (TGF-β) is ubiquitously found in bone and plays a key role in bone turnover. Mice expressing constitutively active TGF-β receptor type I (Mx1;TβRICA mice) are osteopenic. Here, we identified the candidate genes involved in bone turnover in Mx1;TβRICA mice using RNA sequencing analysis. A total of 285 genes, including 87 upregulated and 198 downregulated genes, were differentially expressed. According to the KEGG analysis, some genes were involved in osteoclast differentiation (Fcgr4, Lilrb4a), B cell receptor signaling (Cd72, Lilrb4a), and neutrophil extracellular trap formation (Hdac7, Padi4). Lilrb4 is related to osteoclast inhibition protein, whereas Hdac7 is a Runx2 corepressor that regulates osteoblast differentiation. Silencing Lilrb4 increased the number of osteoclasts and osteoclast marker genes. The knocking down of Hdac7 increased alkaline phosphatase activity, mineralization, and osteoblast marker genes. Therefore, our present study may provide an innovative idea for potential therapeutic targets and pathways in TβRI-associated bone loss.